celecoxib and Cholera Infantum studies

Research Excerpts

Excerpt	Relevance	Reference
"NAXOZOL was not inferior to celecoxib in protecting the gastrointestinal tract and providing pain relief in patients with osteoarthritis."	9.34	A comparative study of the efficacy of NAXOZOL compared to celecoxib in patients with osteoarthritis. ( Kang, CN; Kim, HJ; Kim, JH; Lee, S; Lee, WS; Moon, SH; Park, MS; Shin, SJ, 2020)
"Patients who required NSAIDs for osteoarthritis or rheumatoid arthritis and were at increased cardiovascular risk were randomly assigned to receive celecoxib, ibuprofen, or naproxen."	9.22	Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. ( Bao, W; Beckerman, B; Berger, MF; Borer, JS; Gaffney, M; Graham, DY; Husni, ME; Libby, P; Lincoff, AM; Lüscher, TF; Menon, V; Nissen, SE; Ruschitzka, F; Solomon, DH; Wang, Q; Wisniewski, LM; Wolski, KE; Yeomans, ND, 2016)
" The aim of this study was to compare the efficacy and safety profiles of pelubiprofen with those of celecoxib in patients with rheumatoid arthritis."	9.19	Comparison of the efficacy and safety profiles of a pelubiprofen versus celecoxib in patients with rheumatoid arthritis: a 6-week, multicenter, randomized, double-blind, phase III, non-inferiority clinical trial. ( Baek, HJ; Cho, CS; Choi, IA; Chung, WT; Kang, SW; Kim, HA; Lee, J; Lee, SS; Lee, YA; Lee, YJ; Park, YB; Park, YE; Song, JS; Song, YW; Yoo, WH, 2014)
"Genetic polymorphisms in multiple inflammation-related genes appear to interact with celecoxib on adenoma recurrence and its attendant toxicity, particularly cardiovascular toxicity/symptoms."	9.17	Impact of genetic polymorphisms on adenoma recurrence and toxicity in a COX2 inhibitor (celecoxib) trial: results from a pilot study. ( Arber, N; Coghill, AE; Duggan, D; Galazan, L; Gigic, B; Hummler, S; Kazanov, D; Kotzmann, J; Kraus, S; Makar, KW; Naumov, I; Poole, EM; Scherer, D; Toriola, AT; Ulrich, CM, 2013)
"The use of 400 mg of celecoxib once daily significantly reduced the occurrence of colorectal adenomas within three years after polypectomy."	9.12	Celecoxib for the prevention of colorectal adenomatous polyps. ( Arber, N; Bhadra, P; Dite, P; Eagle, CJ; Fowler, R; Gerletti, P; Hajer, J; Lechuga, MJ; Levin, B; Macdonald, K; Rácz, I; Rosenstein, RB; Solomon, SD; Spicak, J; Tang, J; Wittes, J; Zauber, AG; Zavoral, M, 2006)
"We randomly assigned patients who had adenomas removed before study entry to receive placebo (679 patients) or 200 mg (685 patients) or 400 mg (671 patients) of celecoxib twice daily."	9.12	Celecoxib for the prevention of sporadic colorectal adenomas. ( Anderson, WF; Bagheri, D; Bertagnolli, MM; Boisserie, F; Burn, J; Chung, DC; Corle, D; Dewar, T; Eagle, CJ; Foley, TR; Gordon, GB; Hawk, ET; Hess, TM; Hoffman, N; Kim, K; Macrae, F; Pruitt, RE; Redston, M; Rosenstein, RB; Saltzman, JR; Salzberg, B; Solomon, SD; Sylwestrowicz, T; Tang, J; Viner, JL; Wittes, J; Woloj, GM; Zauber, AG, 2006)
"To compare the efficacy of etoricoxib 30 mg with the generally maximum recommended dose of celecoxib, 200 mg, in the treatment of osteoarthritis (OA) in two identically designed studies."	9.12	Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies. ( Bingham, CO; Bird, S; Fitzgerald, BJ; Kremer, J; O'Brien, K; Rubin, BR; Ruoff, GE; Sebba, AI; Smugar, SS; Tershakovec, AM, 2007)
"To evaluate the relative gastrointestinal (GI) tolerability of celecoxib and rofecoxib in elderly hypertensive patients with osteoarthritis (OA) with or without coadministration of low dose aspirin (ASA) (< or = 325 mg daily)."	9.11	Cyclooxygenase-2 specific inhibitors and upper gastrointestinal tolerability in patients with osteoarthritis receiving concomitant low dose aspirin: pooled analysis of 2 trials. ( Bello, AE; Fort, JG; Goldstein, JL; Spalding, W; Suh, S, 2005)
"The objective was to improve understanding of adverse events occurring with celecoxib in the treatment of osteoarthritis and rheumatoid arthritis."	8.82	Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports. ( Derry, S; Makinson, GT; McQuay, HJ; Moore, RA, 2005)
"Celecoxib is as effective as other NSAIDs for relief of symptoms of osteoarthritis and rheumatoid arthritis and has significantly improved gastrointestinal safety and tolerability."	8.81	Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. ( Bradley, MD; Deeks, JJ; Smith, LA, 2002)
"The aim of this study was to examine the cost-effectiveness of branded and authorized generic (AG) celecoxib for chronic pain patients with osteoarthritis (OA), rheumatoid arthritis (RA), and low back pain (LBP), using real-world cost information for loxoprofen and pharmacotherapy for gastrointestinal bleeding."	8.02	Cost-effectiveness analysis of branded and authorized generic celecoxib for patients with chronic pain in Japan. ( Kamae, I; Karasawa, Y; Murata, T; Nozawa, K; Sakamoto, C; Soen, S; Zeniya, S, 2021)
"The Arthritis Cost Consequence Evaluation System (ACCES) pharmacoeconomic model was used to evaluate the economic and health impact of the recent introduction of celecoxib for treatment of osteoarthritis (OA) and rheumatoid arthritis (RA) in Sweden."	7.70	The Swedish ACCES model: predicting the health economic impact of celecoxib in patients with osteoarthritis or rheumatoid arthritis. ( Haglund, U; Svarvar, P, 2000)
"In this study, celecoxib, at dosages greater than those indicated clinically, was associated with a lower incidence of symptomatic ulcers and ulcer complications combined, as well as other clinically important toxic effects, compared with NSAIDs at standard dosages."	6.69	Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. ( Agrawal, NM; Burr, AM; Eisen, G; Faich, G; Geis, GS; Goldstein, JL; Kent, JD; Lefkowith, JB; Makuch, R; Pincus, T; Silverstein, FE; Simon, LS; Stenson, WF; Verburg, KM; Whelton, A; Zhao, WW, 2000)
"NAXOZOL was not inferior to celecoxib in protecting the gastrointestinal tract and providing pain relief in patients with osteoarthritis."	5.34	A comparative study of the efficacy of NAXOZOL compared to celecoxib in patients with osteoarthritis. ( Kang, CN; Kim, HJ; Kim, JH; Lee, S; Lee, WS; Moon, SH; Park, MS; Shin, SJ, 2020)
"Celecoxib was dominated by diclofenac in average-risk patients."	5.32	The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis. ( Krahn, M; Maetzel, A; Naglie, G, 2003)
" Osteoarthritis or rheumatoid arthritis patients, needing ongoing NSAID treatment, were randomised to receive celecoxib 100-200 mg b."	5.27	Randomised clinical trial: gastrointestinal events in arthritis patients treated with celecoxib, ibuprofen or naproxen in the PRECISION trial. ( Bao, W; Borer, JS; Graham, DY; Husni, ME; Libby, P; Lincoff, AM; Lüscher, TF; Nissen, SE; Solomon, DH; Stevens, T; Vargo, J; Walker, C; Wang, Q; Wisniewski, LM; Wolski, KE; Yeomans, ND, 2018)
"To determine the relative risks of cardiovascular (CV), gastrointestinal (GI), and renal adverse events during long-term treatment with celecoxib, compared with ibuprofen and naproxen, in patients with osteoarthritis (OA) and patients with rheumatoid arthritis (RA)."	5.27	Differences in Safety of Nonsteroidal Antiinflammatory Drugs in Patients With Osteoarthritis and Patients With Rheumatoid Arthritis: A Randomized Clinical Trial. ( Bao, W; Berger, MF; Borer, JS; Graham, DY; Husni, ME; Libby, P; Lincoff, AM; Lüscher, TF; Menon, V; Nissen, SE; Solomon, DH; Wang, Q; Wisniewski, LM; Wolski, KE; Yeomans, ND, 2018)
"Patients who required NSAIDs for osteoarthritis or rheumatoid arthritis and were at increased cardiovascular risk were randomly assigned to receive celecoxib, ibuprofen, or naproxen."	5.22	Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. ( Bao, W; Beckerman, B; Berger, MF; Borer, JS; Gaffney, M; Graham, DY; Husni, ME; Libby, P; Lincoff, AM; Lüscher, TF; Menon, V; Nissen, SE; Ruschitzka, F; Solomon, DH; Wang, Q; Wisniewski, LM; Wolski, KE; Yeomans, ND, 2016)
" The aim of this study was to compare the efficacy and safety profiles of pelubiprofen with those of celecoxib in patients with rheumatoid arthritis."	5.19	Comparison of the efficacy and safety profiles of a pelubiprofen versus celecoxib in patients with rheumatoid arthritis: a 6-week, multicenter, randomized, double-blind, phase III, non-inferiority clinical trial. ( Baek, HJ; Cho, CS; Choi, IA; Chung, WT; Kang, SW; Kim, HA; Lee, J; Lee, SS; Lee, YA; Lee, YJ; Park, YB; Park, YE; Song, JS; Song, YW; Yoo, WH, 2014)
"Genetic polymorphisms in multiple inflammation-related genes appear to interact with celecoxib on adenoma recurrence and its attendant toxicity, particularly cardiovascular toxicity/symptoms."	5.17	Impact of genetic polymorphisms on adenoma recurrence and toxicity in a COX2 inhibitor (celecoxib) trial: results from a pilot study. ( Arber, N; Coghill, AE; Duggan, D; Galazan, L; Gigic, B; Hummler, S; Kazanov, D; Kotzmann, J; Kraus, S; Makar, KW; Naumov, I; Poole, EM; Scherer, D; Toriola, AT; Ulrich, CM, 2013)
"To compare the efficacy of etoricoxib 30 mg with the generally maximum recommended dose of celecoxib, 200 mg, in the treatment of osteoarthritis (OA) in two identically designed studies."	5.12	Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies. ( Bingham, CO; Bird, S; Fitzgerald, BJ; Kremer, J; O'Brien, K; Rubin, BR; Ruoff, GE; Sebba, AI; Smugar, SS; Tershakovec, AM, 2007)
"The use of 400 mg of celecoxib once daily significantly reduced the occurrence of colorectal adenomas within three years after polypectomy."	5.12	Celecoxib for the prevention of colorectal adenomatous polyps. ( Arber, N; Bhadra, P; Dite, P; Eagle, CJ; Fowler, R; Gerletti, P; Hajer, J; Lechuga, MJ; Levin, B; Macdonald, K; Rácz, I; Rosenstein, RB; Solomon, SD; Spicak, J; Tang, J; Wittes, J; Zauber, AG; Zavoral, M, 2006)
"We randomly assigned patients who had adenomas removed before study entry to receive placebo (679 patients) or 200 mg (685 patients) or 400 mg (671 patients) of celecoxib twice daily."	5.12	Celecoxib for the prevention of sporadic colorectal adenomas. ( Anderson, WF; Bagheri, D; Bertagnolli, MM; Boisserie, F; Burn, J; Chung, DC; Corle, D; Dewar, T; Eagle, CJ; Foley, TR; Gordon, GB; Hawk, ET; Hess, TM; Hoffman, N; Kim, K; Macrae, F; Pruitt, RE; Redston, M; Rosenstein, RB; Saltzman, JR; Salzberg, B; Solomon, SD; Sylwestrowicz, T; Tang, J; Viner, JL; Wittes, J; Woloj, GM; Zauber, AG, 2006)
"To evaluate the relative gastrointestinal (GI) tolerability of celecoxib and rofecoxib in elderly hypertensive patients with osteoarthritis (OA) with or without coadministration of low dose aspirin (ASA) (< or = 325 mg daily)."	5.11	Cyclooxygenase-2 specific inhibitors and upper gastrointestinal tolerability in patients with osteoarthritis receiving concomitant low dose aspirin: pooled analysis of 2 trials. ( Bello, AE; Fort, JG; Goldstein, JL; Spalding, W; Suh, S, 2005)
"The objective was to improve understanding of adverse events occurring with celecoxib in the treatment of osteoarthritis and rheumatoid arthritis."	4.82	Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports. ( Derry, S; Makinson, GT; McQuay, HJ; Moore, RA, 2005)
"Celecoxib is as effective as other NSAIDs for relief of symptoms of osteoarthritis and rheumatoid arthritis and has significantly improved gastrointestinal safety and tolerability."	4.81	Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. ( Bradley, MD; Deeks, JJ; Smith, LA, 2002)
"The aim of this study was to examine the cost-effectiveness of branded and authorized generic (AG) celecoxib for chronic pain patients with osteoarthritis (OA), rheumatoid arthritis (RA), and low back pain (LBP), using real-world cost information for loxoprofen and pharmacotherapy for gastrointestinal bleeding."	4.02	Cost-effectiveness analysis of branded and authorized generic celecoxib for patients with chronic pain in Japan. ( Kamae, I; Karasawa, Y; Murata, T; Nozawa, K; Sakamoto, C; Soen, S; Zeniya, S, 2021)
" In a cohort study comparing the risk of upper gastrointestinal complications in celecoxib or traditional NSAIDs (diclofenac, ibuprofen) initiators with rheumatoid arthritis and osteoarthritis, we (1) aggregated medications and International Classification of Diseases-9 (ICD-9) diagnoses into hierarchies of the Anatomical Therapeutic Chemical classification (ATC) and the Clinical Classification Software (CCS), respectively, and (2) sampled the full cohort using techniques validated by simulations to create 9,600 samples to compare 16 aggregation scenarios across 50% and 20% samples with varying outcome incidence and exposure prevalence."	3.79	Effects of aggregation of drug and diagnostic codes on the performance of the high-dimensional propensity score algorithm: an empirical example. ( Beach, KJ; Brookhart, MA; Layton, JB; Le, HV; Poole, C; Schoenbach, VJ; Stürmer, T, 2013)
"To compare the incidence of serious gastrointestinal (GI) complications and associated medical costs in a population with either osteoarthritis (OA) or rheumatoid arthritis (RA) enrolled in Medicare plans with celecoxib formulary restrictions versus plans without such restrictions."	3.77	Impact of Celecoxib restrictions in medicare beneficiaries with arthritis. ( Ball, AT; Cappelleri, JC; Deminski, MC; Joshi, AV; Louder, AM; Sanchez, RJ, 2011)
"This literature-based economic analysis (with data summarized from MEDLINE-indexed and other published sources, FDA reports, and data on file at VA San Diego Healthcare System) compared rofecoxib and celecoxib to NSAIDS in two arthritis patient populations considered at higher risk of developing clinically significant upper gastrointestinal events (CSUGIEs): (1) patients of any age with previous medical history of perforation/ulcer/bleed (PUB); and (2) patients 65 years and older (regardless of history of PUB)."	3.73	Assessing the cost-effectiveness of COX-2 specific inhibitors for arthritis in the Veterans Health Administration. ( Botteman, M; DeLattre, M; Gao, X; Morreale, A; Schaefer, M; Stephens, J, 2005)
"To simultaneously assess the short-term reduction in risk of gastrointestinal (GI) complications and increase in risk of acute myocardial infarction (MI) by celecoxib compared with rofecoxib and several nonselective nonsteroidal antiinflammatory drugs (NSAIDs) using instrumental variable analysis."	3.73	Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis. ( Brookhart, MA; Rassen, J; Schneeweiss, S; Solomon, DH; Wang, PS, 2006)
"Celecoxib appeared to be the least costly alternative in patients with intermediate to high gastrointestinal risk for the treatment of osteoarthritis and rheumatoid arthritis in Hong Kong."	3.71	Arthritis treatment in Hong Kong--cost analysis of celecoxib versus conventional NSAIDS, with or without gastroprotective agents. ( Chan, FK; Chan, TY; Lau, WH; Lee, KK; You, JH, 2002)
"A population of 6637 patients with rheumatoid arthritis (RA) and osteoarthritis (OA) from the practices of 433 US rheumatologists completed 2 sets of detailed questionnaires concerning (1) the last 6 months in 1998 and (2) the first 6 months of 1999, generally prior to and after the release of celecoxib and rofecoxib."	3.71	Increase in lifetime adverse drug reactions, service utilization, and disease severity among patients who will start COX-2 specific inhibitors: quantitative assessment of channeling bias and confounding by indication in 6689 patients with rheumatoid arthr ( Arguelles, LM; Burke, TA; Flowers, N; Pettitt, D; Wolfe, F, 2002)
"The Arthritis Cost Consequence Evaluation System (ACCES) pharmacoeconomic model was used to evaluate the economic and health impact of the recent introduction of celecoxib for treatment of osteoarthritis (OA) and rheumatoid arthritis (RA) in Sweden."	3.70	The Swedish ACCES model: predicting the health economic impact of celecoxib in patients with osteoarthritis or rheumatoid arthritis. ( Haglund, U; Svarvar, P, 2000)
" Other outcome measures included adverse events (AEs), laboratory tests, vital signs, electrocardiograms, and physical examinations."	2.84	A Randomized, Multicenter, Phase III Trial to Evaluate the Efficacy and Safety of Polmacoxib Compared with Celecoxib and Placebo for Patients with Osteoarthritis. ( Bin, SI; Cho, S; Choi, CH; Han, SB; In, Y; Kang, SB; Kim, J; Kim, JG; Kim, YM; Kyung, HS; Lee, BK; Lee, M; Moon, YW; Yoo, J, 2017)
" These results indicate GCSB-5 is safe for a long-term treatment of knee OA patients."	2.82	Gastrointestinal safety and efficacy of long-term GCSB-5 use in patients with osteoarthritis: A 24-week, multicenter study. ( Bae, KC; Bin, SI; Cho, SD; Choi, ES; Ha, CW; Han, CS; Kang, JS; Kim, CW; Kim, JG; Kyung, HS; Lee, DC; Lee, JH; Lee, MC; Lee, WS; Lim, HC; Park, SE; Park, YB; Seon, JK; Won, YY, 2016)
"Celecoxib was predefined to be noninferior to placebo if the upper limit of the 95% CI for the hazard ratio (HR) with celecoxib was <1."	2.77	The APC and PreSAP trials: a post hoc noninferiority analysis using a comprehensive new measure for gastrointestinal tract injury in 2 randomized, double-blind studies comparing celecoxib and placebo. ( Arber, N; Bertagnolli, MM; Coindreau, J; Eagle, C; Hawk, ET; Lanas, A; Levin, B; Lieberman, D; Sands, GH; Wang, TC; Zauber, A; Zhang, R, 2012)
"Celecoxib dosage was fixed."	2.75	A phase I study of capecitabine, irinotecan, celecoxib, and radiation as neoadjuvant therapy of patients with locally advanced rectal cancer. ( Alqaisi, M; Bernal, P; Bush, D; Byrd, J; Garberoglio, C; Hussein, F; Malik, I, 2010)
"Ibuprofen liquigel is an encapsulated, solubilized potassium salt of ibuprofen that has a higher Cmax and shorter tmax than traditional ibuprofen solid-dosage formulations."	2.70	Efficacy and tolerability of nonprescription ibuprofen versus celecoxib for dental pain. ( Ashraf, E; Cooper, SA; Doyle, G; Jayawardena, S, 2002)
"Diclofenac-treated patients experienced statistically significant elevations in mean hepatic transaminases and serum creatinine and reductions in haemoglobin concentration when compared to placebo, events not observed with celecoxib."	2.70	Celecoxib versus diclofenac in the management of osteoarthritis of the knee. ( Borenstein, D; Geis, GS; Lefkowith, JB; McKenna, F; Wallemark, C; Wendt, H, 2001)
"In this study, celecoxib, at dosages greater than those indicated clinically, was associated with a lower incidence of symptomatic ulcers and ulcer complications combined, as well as other clinically important toxic effects, compared with NSAIDs at standard dosages."	2.69	Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. ( Agrawal, NM; Burr, AM; Eisen, G; Faich, G; Geis, GS; Goldstein, JL; Kent, JD; Lefkowith, JB; Makuch, R; Pincus, T; Silverstein, FE; Simon, LS; Stenson, WF; Verburg, KM; Whelton, A; Zhao, WW, 2000)
" For the comparison in between the two dosage regimens, 100 mg BID oral celecoxib exhibited a greater probability to be the preferred one either in terms of pain intensity or function at the last follow-up time point."	2.52	Comparison between 200 mg QD and 100 mg BID oral celecoxib in the treatment of knee or hip osteoarthritis. ( Gao, SG; Lei, GH; Li, H; Li, YS; Luo, W; Wei, J; Xiao, WF; Xiong, YL; Yang, T; Yang, TB; Zeng, C, 2015)
" This article critically reviews the data on gastrointestinal toxic side effects for conventional NSAIDs without as well as with prevention therapy."	2.41	Gastrointestinal toxic side effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2-specific inhibitors. ( Burmester, GR; Buttgereit, F; Simon, LS, 2001)
" Patients prescribed CSIs (or NSAIDs) should be reviewed within the first few weeks of therapy to assess effectiveness, identify adverse effects and determine the need for ongoing therapy."	2.41	Considerations for the safe prescribing and use of COX-2-specific inhibitors. ( , 2002)
"The main GI and CV adverse events associated with NSAID use are reviewed."	1.72	Gastrointestinal and cardiovascular adverse events associated with NSAIDs. ( Domper Arnal, MJ; Hijos-Mallada, G; Lanas, A, 2022)
"Gastrointestinal disorders were the most frequently reported adverse events at the system organ class (SOC) level in the AERs."	1.51	Potentially inappropriate concomitant medicine use with the selective COX-2 inhibitor celecoxib: Analysis and comparison of spontaneous adverse event reports from Australia, Canada and the USA. ( Ahmed, R; Baselyous, Y; De Cocinis, M; Ibrahim, M; Kalra, A; Yacoub, R, 2019)
" The objective of this study was to evaluate the risk of upper GI adverse events associated with celecoxib and oral and parenteral non-selective NSAIDs in cirrhotic patients."	1.38	Non-steroidal anti-inflammatory drugs use and risk of upper gastrointestinal adverse events in cirrhotic patients. ( Chang, CH; Chen, HC; Lai, MS; Lee, YC; Lin, JW; Lin, MS, 2012)
"A total of 40,635 patients hospitalized for upper GI adverse events were included."	1.37	Risk of hospitalization for upper gastrointestinal adverse events associated with nonsteroidal anti-inflammatory drugs: a nationwide case-crossover study in Taiwan. ( Chang, CH; Chen, HC; Kuo, CW; Lai, MS; Lin, JW; Shau, WY, 2011)
"Endoscopy was performed to document any gastroduodenal ulcers with or without ulcer complications."	1.36	Incidence and possible risk factors for clinical upper gastrointestinal events in patients taking selective cyclooxygenase-2 inhibitors: A prospective, observational, cohort study in Taiwan. ( Chang, FY; Chen, TS; Hsiang, KW; Lee, KC; Lee, SD; Lin, HC; Lin, HY; Lu, CL; Luo, JC, 2010)
" A dose-response relationship was observed for rofecoxib and naproxen with ORs for high dose of 5."	1.35	Risk of upper gastrointestinal complications associated with cyclooxygenase-2 selective and nonselective nonsteroidal antiinflammatory drugs. ( Castellsague, J; Gimeno, V; Hoffman, CC; Holick, CN; Perez-Gutthann, S; Stang, MR, 2009)
"Celecoxib was dominated by diclofenac in average-risk patients."	1.32	The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis. ( Krahn, M; Maetzel, A; Naglie, G, 2003)

Research

Studies (89)

Authors

Clinical Trials (13)

Trial Overview

Trial Outcomes

Change From Baseline in Patient's Assessment of Arthritis Pain (VAS)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	2 (2.25)	18.2507
2000's	61 (68.54)	29.6817
2010's	23 (25.84)	24.3611
2020's	3 (3.37)	2.80

Authors	Studies
Park, MS	1
Kang, CN	1
Lee, WS	2
Kim, HJ	1
Lee, S	1
Kim, JH	1
Shin, SJ	1
Moon, SH	1
Karasawa, Y	1
Kamae, I	1
Nozawa, K	1
Zeniya, S	1
Murata, T	1
Soen, S	1
Sakamoto, C	1
Domper Arnal, MJ	1
Hijos-Mallada, G	1
Lanas, A	3
Lee, M	1
Yoo, J	1
Kim, JG	2
Kyung, HS	2
Bin, SI	2
Kang, SB	1
Choi, CH	2
Moon, YW	1
Kim, YM	1
Han, SB	1
In, Y	1
Kim, J	1
Lee, BK	1
Cho, S	1
Solomon, DH	4
Husni, ME	3
Wolski, KE	3
Wisniewski, LM	3
Borer, JS	3
Graham, DY	3
Libby, P	3
Lincoff, AM	3
Lüscher, TF	3
Menon, V	2
Yeomans, ND	3
Wang, Q	3
Bao, W	3
Berger, MF	2
Nissen, SE	3
Stevens, T	1
Vargo, J	1
Walker, C	1
Lai, EC	1
Shin, JY	1
Kubota, K	1
Man, KKC	1
Park, BJ	1
Pratt, N	1
Roughead, EE	1
Wong, ICK	1
Kao Yang, YH	1
Setoguchi, S	1
Baselyous, Y	1
De Cocinis, M	1
Ibrahim, M	1
Kalra, A	1
Yacoub, R	1
Ahmed, R	1
Kraus, S	1
Hummler, S	1
Toriola, AT	1
Poole, EM	1
Scherer, D	1
Kotzmann, J	1
Makar, KW	1
Kazanov, D	1
Galazan, L	1
Naumov, I	1
Coghill, AE	1
Duggan, D	1
Gigic, B	1
Arber, N	3
Ulrich, CM	1
Le, HV	1
Poole, C	1
Brookhart, MA	2
Schoenbach, VJ	1
Beach, KJ	1
Layton, JB	1
Stürmer, T	1
Sostres, C	1
Gargallo, CJ	1
Choi, IA	1
Baek, HJ	1
Cho, CS	1
Lee, YA	1
Chung, WT	1
Park, YE	1
Lee, YJ	1
Park, YB	2
Lee, J	1
Lee, SS	1
Yoo, WH	1
Song, JS	1
Kang, SW	1
Kim, HA	1
Song, YW	1
Zeng, C	1
Wei, J	1
Li, H	1
Yang, T	1
Gao, SG	1
Li, YS	1
Xiong, YL	1
Xiao, WF	1
Luo, W	1
Yang, TB	1
Lei, GH	1
Ha, CW	1
Han, CS	1
Bae, KC	1
Lim, HC	1
Park, SE	1
Lee, MC	1
Won, YY	1
Lee, DC	1
Cho, SD	1
Kim, CW	1
Kang, JS	1
Lee, JH	1
Choi, ES	1
Seon, JK	1
Ruschitzka, F	1
Gaffney, M	1
Beckerman, B	1
Malik, I	1
Hussein, F	1
Bush, D	1
Alqaisi, M	1
Bernal, P	1
Byrd, J	1
Garberoglio, C	1
Castellsague, J	1
Holick, CN	1
Hoffman, CC	1
Gimeno, V	1
Stang, MR	1
Perez-Gutthann, S	1
Hsiang, KW	1
Chen, TS	1
Lin, HY	1
Luo, JC	1
Lu, CL	1
Lin, HC	1
Lee, KC	1
Chang, FY	1
Lee, SD	1
Mallen, SR	1
Essex, MN	2
Zhang, R	2
Chang, CH	2
Chen, HC	2
Lin, JW	2
Kuo, CW	1
Shau, WY	1
Lai, MS	2
Louder, AM	1
Joshi, AV	1
Ball, AT	1
Cappelleri, JC	1
Deminski, MC	1
Sanchez, RJ	1
Lee, YC	1
Lin, MS	1
Lieberman, D	1
Wang, TC	1
Sands, GH	2
Bertagnolli, MM	2
Hawk, ET	2
Eagle, C	1
Coindreau, J	1
Zauber, A	1
Levin, B	2
Blackler, R	1
Syer, S	1
Bolla, M	1
Ongini, E	1
Wallace, JL	2
Bhadra, P	2
Wielage, R	1
Bansal, M	1
Wilson, K	1
Klein, R	1
Happich, M	1
Hasegawa, M	1
Horiki, N	1
Tanaka, K	1
Wakabayashi, H	1
Tano, S	1
Katsurahara, M	1
Uchida, A	1
Takei, Y	1
Sudo, A	1
Budenholzer, BR	1
Doyle, G	1
Jayawardena, S	1
Ashraf, E	1
Cooper, SA	1
Deeks, JJ	1
Smith, LA	1
Bradley, MD	1
Wright, JM	1
You, JH	1
Lee, KK	1
Chan, TY	1
Lau, WH	1
Chan, FK	1
Oms Arias, M	1
Morral Parente, RM	1
Micklewright, R	1
Lane, S	1
Linley, W	1
McQuade, C	1
Thompson, F	1
Maskrey, N	1
Metcalfe, S	2
Dougherty, S	1
McNee, W	1
Maetzel, A	1
Krahn, M	1
Naglie, G	1
Layton, D	2
Hughes, K	1
Harris, S	2
Shakir, SA	2
Verrico, MM	1
Weber, RJ	1
McKaveney, TP	1
Ansani, NT	1
Towers, AL	1
LeLorier, J	1
Fitzsimon, C	1
Keresteci, M	1
Stewart, D	1
Lavoie, F	1
Alvaro-Gracia, JM	1
Perini, R	1
Fiorucci, S	1
Zhao, SZ	1
Wentworth, C	1
Burke, TA	2
Makuch, RW	1
Dickman, A	1
Ellershaw, J	1
de Leval, X	1
Julémont, F	1
Benoit, V	1
Frederich, M	1
Pirotte, B	1
Dogné, JM	1
Fitzgerald, GA	2
Lugardon, S	1
Lapeyre-Mestre, M	1
Montastruc, JL	1
Wolfe, MM	2
Goldstein, JL	2
Bello, AE	1
Spalding, W	1
Suh, S	1
Fort, JG	1
Evensen, S	1
Spigset, O	1
Slørdal, L	1
Spiegel, BM	1
Chiou, CF	1
Ofman, JJ	1
Schaefer, M	1
DeLattre, M	1
Gao, X	1
Stephens, J	1
Botteman, M	1
Morreale, A	1
Moore, RA	1
Derry, S	1
Makinson, GT	1
McQuay, HJ	1
Kasliwal, R	1
Wilton, L	1
Bingham, CO	1
Sebba, AI	1
Rubin, BR	1
Ruoff, GE	1
Kremer, J	1
Bird, S	1
Smugar, SS	1
Fitzgerald, BJ	1
O'Brien, K	1
Tershakovec, AM	1
Eagle, CJ	2
Zauber, AG	2
Redston, M	1
Solomon, SD	2
Kim, K	1
Tang, J	2
Rosenstein, RB	2
Wittes, J	2
Corle, D	1
Hess, TM	1
Woloj, GM	1
Boisserie, F	1
Anderson, WF	1
Viner, JL	1
Bagheri, D	1
Burn, J	1
Chung, DC	1
Dewar, T	1
Foley, TR	1
Hoffman, N	1
Macrae, F	1
Pruitt, RE	1
Saltzman, JR	1
Salzberg, B	1
Sylwestrowicz, T	1
Gordon, GB	1
Spicak, J	1
Rácz, I	1
Dite, P	1
Hajer, J	1
Zavoral, M	1
Lechuga, MJ	1
Gerletti, P	1
Macdonald, K	1
Fowler, R	1
Herrera, FG	1
Chan, P	1
Doll, C	1
Milosevic, M	1
Oza, A	1
Syed, A	1
Pintilie, M	1
Levin, W	1
Manchul, L	1
Fyles, A	1
Schneeweiss, S	1
Wang, PS	1
Rassen, J	1
Depont, F	1
Fourrier, A	1
Merlière, Y	1
Droz, C	1
Amouretti, M	1
Bégaud, B	1
Bénichou, J	1
Moride, Y	1
Velo, GP	1
Sturkenboom, M	1
Blin, P	1
Moore, N	1
Caldwell, B	1
Beasley, R	1
Weatherall, M	1
Sieper, J	1
Klopsch, T	1
Richter, M	1
Kapelle, A	1
Rudwaleit, M	1
Schwank, S	1
Regourd, E	1
May, M	1
Targownik, LE	1
Metge, CJ	1
Leung, S	1
Chateau, DG	1
van Staa, TP	1
Smeeth, L	1
Persson, I	1
Parkinson, J	1
Leufkens, HG	1
Fleischmann, R	1
Tannenbaum, H	1
Patel, NP	1
Notter, M	1
Sallstig, P	1
Reginster, JY	1
Miller, JL	1
Soto Alvarez, J	1
Fernandez, H	1
Lesser, GT	1
Palmer, RH	1
Silverstein, FE	1
Faich, G	1
Simon, LS	2
Pincus, T	1
Whelton, A	1
Makuch, R	1
Eisen, G	1
Agrawal, NM	1
Stenson, WF	1
Burr, AM	1
Zhao, WW	1
Kent, JD	1
Lefkowith, JB	2
Verburg, KM	1
Geis, GS	2
Lichtenstein, DR	1
Brooks, PM	1
Day, RO	1
Cannon, GW	1
Breedveld, FC	1
Buttgereit, F	1
Burmester, GR	1
Dougados, M	1
Béhier, JM	1
Jolchine, I	1
Calin, A	1
van der Heijde, D	1
Olivieri, I	1
Zeidler, H	1
Herman, H	1
Taylor, B	1
van de Wal, B	1
Mbewu, A	1
McKenna, F	1
Borenstein, D	1
Wendt, H	1
Wallemark, C	1
Lichtenberger, LM	1
Haglund, U	1
Svarvar, P	1
Pasero, C	1
McCaffery, M	1
Graumlich, JF	1
Bannwarth, B	1
Patrono, C	1
Cleland, LG	1
James, MJ	1
Stamp, LK	1
Penglis, PS	1
Weaver, J	1
Bonnel, RA	1
Karwoski, CB	1
Brinker, AD	1
Beitz, J	1
Capriotti, T	1
Wolfe, F	1
Flowers, N	1
Arguelles, LM	1
Pettitt, D	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Randomized, Double Blind, Parallel-group Study Of Cardiovascular Safety In Osteoarthritis Or Rheumatoid Arthritis Patients With Or At High Risk For Cardiovascular Disease Comparing Celecoxib With Naproxen And Ibuprofen[NCT00346216]	Phase 4	24,081 participants (Actual)	Interventional	2006-10-04	Completed
A Randomized, Double-blind, Multicenter, Phase 3 Study of Pelubiprofen Tab. & Celebrex Cap. for Comparative Evaluation of Safety & Efficacy in Rheumatoid Arthritis Patients[NCT01781702]	Phase 3	120 participants (Actual)	Interventional	2010-10-31	Completed
A 24 Weeks, Multi-centers, Single Arm Phase IV Study to Evaluate the Safety of 'Shinbaro Capsule' Compared With Historical Data of 'Celebrex Capsule' in Patients With Osteoarthritis[NCT01604239]	Phase 4	761 participants (Actual)	Interventional	2012-05-31	Completed
Single Dose Oral Celecoxib (With or Without Acetaminophen) for Acute Post-operative Pain Following Impacted Third Molar Surgery.[NCT04790812]	Phase 4	100 participants (Anticipated)	Interventional	2021-04-22	Recruiting
Use of a Self-Guided Mindfulness Mobile Application to Improve Pain Outcomes in Individuals With Knee Osteoarthritis[NCT03936088]		75 participants (Actual)	Interventional	2019-05-02	Completed
Clinical Protocol For a Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Celecoxib (SC-58635) In The Prevention of Colorectal Sporadic Adenomatous Polyps (PRESAP)[NCT00141193]	Phase 3	1,561 participants (Actual)	Interventional	2001-02-28	Completed
Prevention of Sporadic Colorectal Adenomas With Celecoxib[NCT00005094]	Phase 3	1,170 participants (Anticipated)	Interventional	2000-03-31	Completed
A 26-Week, Randomized, Placebo- and Active-Comparator-Controlled, Parallel-Group, Double-Blind, 2-Part Study to Assess the Safety and Efficacy of Etoricoxib 30 mg Versus Celecoxib 200 mg in Patients With Osteoarthritis (Study 2)[NCT00092781]	Phase 3	500 participants (Actual)	Interventional	2004-03-01	Completed
A 26-Week, Randomized, Placebo- and Active-Comparator-Controlled, Parallel-Group, Double-Blind, 2-Part Study to Assess the Safety and Efficacy of Etoricoxib 30 mg Versus Celecoxib 200 mg in Patients With Osteoarthritis (Study 1)[NCT00092768]	Phase 3	500 participants (Actual)	Interventional	2004-03-01	Completed
Celecoxib for the Treatment of Non-muscle Invasive Bladder Cancer[NCT02343614]	Phase 2	58 participants (Actual)	Interventional	2003-03-31	Completed
A 52-week, International, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Clinical Trial to Compare Retention on Treatment, Safety, Tolerability and Efficacy of Lumiracoxib 100 mg od, Lumiracoxib 100 mg Bid and Celecoxib 200 mg od in [NCT00145301]	Phase 3	3,036 participants	Interventional	2004-09-30	Completed
A Placebo-Controlled, Double-Blind, Randomized Study of the Potential Interaction Between Aspirin and Ibuprofen or Celecoxib.[NCT00565500]	Phase 4	24 participants (Actual)	Interventional	2003-04-30	Completed
Clinical Phase II Pilot Study of the Efficacy of FANG(30) to Treat Active Rheumatoid Arthritis in Adult Patients[NCT00749645]	Phase 2	60 participants (Actual)	Interventional	2006-10-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

"VAS question How much pain do you have was graded on a scale from 0 to 100 with 0 indicating No pain and 100 indicating Worst possible pain." (NCT00346216)
Timeframe: ITT and MITT Population - Baseline to 42 months

The First Occurrence of a Major Adverse Cardiovascular Events (MACE)

Intervention	Number of participants (Mean)
	Baseline (ITT) N= 8014, 8001, 7928	Change-Baseline to Mon1 (ITT) N=7382, 7379, 7325	Change-Baseline to Mon2 (ITT) N=7180, 7090, 7149	Change-Baseline to Mon4 (ITT) N=6777, 6696, 6740	Change-Baseline to Mon8 (ITT) N=6230, 6137, 6159	Change-Baseline to Mon12 (ITT) N=5792, 5696, 5846	Change-Baseline to Mon18 (ITT) N=5310, 5181. 5246	Change-Baseline to Mon24 (ITT) N=4818, 4776, 4785	Change-Baseline to Mon30 (ITT) N=4140, 4069, 4086	Change-Baseline to Mon36 (ITT) N=3692, 3627, 3635	Change-Baseline to Mon42 (ITT) N=3469, 3406, 3439	Baseline (MITT) N=7974, 7954, 7894	Change-Baseline to Mon1 MITT N=7372, 7367, 7321	Change-Baseline to Mon2 MITT N=7170, 7078, 7142	Change-Baseline to Mon4 MITT N=6772, 6686, 6732	Change-Baseline to Mon8 MITT N=6224, 6128, 6155	Change-Baseline to Mon12 MITT N=5787, 5689, 5844	Change-Baseline to Mon18 MITT N=5305, 5175, 5242	Change-Baseline to Mon24 MITT N=4815, 4769, 4782	Change-Baseline to Mon30 MITT N=4139, 4067, 4085	Change-Baseline to Mon36 MITT N=3691, 3623, 3635	Change-Baseline to Mon42 MITT N=3468, 3404, 3438
Celecoxib	54.0	-8.2	-10.5	-11.4	-11.7	-11.0	-11.3	-11.3	-10.5	-10.1	-11.4	54.0	-8.2	-10.5	-11.4	-11.7	-11.0	-11.3	-11.4	-10.5	-10.2	-11.4
Ibuprofen	54.1	-9.0	-10.6	-11.7	-12.1	-11.6	-11.3	-11.5	-11.2	-10.7	-11.1	54.1	-9.0	-10.6	-11.7	-12.1	-11.6	-11.3	-11.5	-11.2	-10.7	-11.1
Naproxen	54.1	-9.9	-11.1	-12.3	-12.1	-11.9	-11.7	-11.4	-11.3	-11.6	-12.1	54.1	-9.9	-11.1	-12.3	-12.1	-11.9	-11.7	-11.3	-11.3	-11.6	-12.1

MACE defined as the composite of CV death (including hemorrhagic death), non-fatal MI, non-fatal stroke, hospitalization for UA, revascularization or hospitalization for TIA (NCT00346216)
Timeframe: ITT Population - 30 months; MITT Population - 42 months

The First Occurrence of Antiplatelet Trialists Collaboration (APTC) Composite Endpoint, Confirmed by the Clinical Events Committee (CEC).

Intervention	Percentage of Participants (Number)
	ITT (N = 8072, 8040, 7969)	MITT (N = 8030, 7990, 7933)
Celecoxib	4.2	3.1
Ibuprofen	4.8	3.6
Naproxen	4.3	3.2

APTC events are defined as a composite of any of the following events: Death due to CV causes (including cardiac, cerebrovascular, venous thromboembolic, haemorrhagic, other vascular, or unknown cause); Non-fatal MI; Non-fatal stroke (including intracranial hemorrhages, stroke of ischemic or unknown etiology). (NCT00346216)
Timeframe: Intent to Treat (ITT) Population - 30 months; Modified ITT (MITT) Population - 42 months

The First Occurrence of Clinically Significant Gastrointestinal Events (CSGIE)

Intervention	Percentage of Partcipants (Number)
	ITT (N = 8072, 8040, 7969)	MITT (N = 8030, 7990, 7933)
Celecoxib	2.3	1.7
Ibuprofen	2.7	1.9
Naproxen	2.5	1.8

CSGIE include: Gastroduodenal (GD) hemorrhage, Gastric outlet obstruction, Gastroduodenal, small bowel or large bowel perforation, Large bowel hemorrhage, Small bowel hemorrhage, Acute GI hemorrhage of unknown origin, including presumed small bowel hemorrhage, Symptomatic gastric or duodenal ulcer (NCT00346216)
Timeframe: ITT Population - 30 months; MITT Population - 42 months

Article	Year
Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage. Arthritis research & therapy, 2013, Volume: 15 Suppl 3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Gastrointestinal Di	2013
Comparison between 200 mg QD and 100 mg BID oral celecoxib in the treatment of knee or hip osteoarthritis. Scientific reports, 2015, May-27, Volume: 5 Topics: Administration, Oral; Celecoxib; Cyclooxygenase 2 Inhibitors; Databases, Factual; Dosage Forms; Gast	2015
Gastrointestinal tolerability of NSAIDs in elderly patients: a pooled analysis of 21 randomized clinical trials with celecoxib and nonselective NSAIDs. Current medical research and opinion, 2011, Volume: 27, Issue:7 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Gastrointestinal Diseases; Gastrointestina	2011
Cost-effectiveness of duloxetine in chronic low back pain: a Quebec societal perspective. Spine, 2013, May-15, Volume: 38, Issue:11 Topics: Age Factors; Aged; Amitriptyline; Analgesics; Cardiovascular Diseases; Celecoxib; Chronic Disease; C	2013
Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. BMJ (Clinical research ed.), 2002, Sep-21, Volume: 325, Issue:7365 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; Celecoxib; Cyclooxygenase I	2002
The double-edged sword of COX-2 selective NSAIDs. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2002, Nov-12, Volume: 167, Issue:10 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Clinical Trials as Topic; Cyclooxygenase Inhibit	2002
Review article: NSAIDs, gastroprotection and cyclo-oxygenase-II-selective inhibitors. Alimentary pharmacology & therapeutics, 2003, Volume: 17, Issue:3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; C	2003
Licofelone--clinical update on a novel LOX/COX inhibitor for the treatment of osteoarthritis. Rheumatology (Oxford, England), 2004, Volume: 43 Suppl 1 Topics: Acetates; Aspirin; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclo	2004
Mechanisms of nonsteroidal anti-inflammatory drug-induced gastrointestinal injury and repair: a window of opportunity for cyclooxygenase-inhibiting nitric oxide donors. Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 2004, Volume: 18, Issue:4 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyc	2004
NSAIDs: gastroprotection or selective COX-2 inhibitor? Palliative medicine, 2004, Volume: 18, Issue:4 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygena	2004
First and second generations of COX-2 selective inhibitors. Mini reviews in medicinal chemistry, 2004, Volume: 4, Issue:6 Topics: Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Etoricoxib; Gas	2004
[COX-2 inhibitors--one step forward and two steps back]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2005, Apr-07, Volume: 125, Issue:7 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase Inhibito	2005
Minimizing complications from nonsteroidal antiinflammatory drugs: cost-effectiveness of competing strategies in varying risk groups. Arthritis and rheumatism, 2005, Apr-15, Volume: 53, Issue:2 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin	2005
Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports. Arthritis research & therapy, 2005, Volume: 7, Issue:3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Drug Industry; Drug Toler	2005
Efficacy of cyclooxygenase-2-specific inhibitors. The American journal of medicine, 2001, Feb-19, Volume: 110 Suppl 3A Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxyge	2001
Gastrointestinal toxic side effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2-specific inhibitors. The American journal of medicine, 2001, Feb-19, Volume: 110 Suppl 3A Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Celecoxib; Cyclooxygenase 2; Cyclooxygen	2001
Celecoxib--is it worth celebrating? South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2000, Volume: 90, Issue:12 Topics: Celecoxib; Consumer Product Safety; Cyclooxygenase Inhibitors; Drug Costs; Gastrointestinal Diseases	2000
Where is the evidence that cyclooxygenase inhibition is the primary cause of nonsteroidal anti-inflammatory drug (NSAID)-induced gastrointestinal injury? Topical injury revisited. Biochemical pharmacology, 2001, Mar-15, Volume: 61, Issue:6 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Gastrointest	2001
Preventing gastrointestinal complications of NSAIDs. Risk factors, recent advances, and latest strategies. Postgraduate medicine, 2001, Volume: 109, Issue:5 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Decision Making; Drug	2001
[COX-2 specific inhibitors: are NSAIDs and the stomach become reconcilied?]. Gastroenterologie clinique et biologique, 2001, Volume: 25, Issue:4 Suppl Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; C	2001
The coxibs, selective inhibitors of cyclooxygenase-2. The New England journal of medicine, 2001, Aug-09, Volume: 345, Issue:6 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cyclooxygena	2001
The coxibs, selective inhibitors of cyclooxygenase-2. The New England journal of medicine, 2001, Aug-09, Volume: 345, Issue:6 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cyclooxygena	2001
The coxibs, selective inhibitors of cyclooxygenase-2. The New England journal of medicine, 2001, Aug-09, Volume: 345, Issue:6 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cyclooxygena	2001
The coxibs, selective inhibitors of cyclooxygenase-2. The New England journal of medicine, 2001, Aug-09, Volume: 345, Issue:6 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cyclooxygena	2001
COX-2 inhibition and thrombotic tendency: a need for surveillance. The Medical journal of Australia, 2001, Aug-20, Volume: 175, Issue:4 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; Celecoxib; Cyclooxygenase I	2001
The new NSAIDs: cox-2 inhibitors. Medsurg nursing : official journal of the Academy of Medical-Surgical Nurses, 2000, Volume: 9, Issue:6 Topics: Advertising; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Celecoxib; Cyclooxygenase 2;	2000
Considerations for the safe prescribing and use of COX-2-specific inhibitors. The Medical journal of Australia, 2002, Apr-01, Volume: 176, Issue:7 Topics: Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase In	2002

Article	Year
A comparative study of the efficacy of NAXOZOL compared to celecoxib in patients with osteoarthritis. PloS one, 2020, Volume: 15, Issue:1 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Celecoxib; Double-Blind Method; Es	2020
A Randomized, Multicenter, Phase III Trial to Evaluate the Efficacy and Safety of Polmacoxib Compared with Celecoxib and Placebo for Patients with Osteoarthritis. Clinics in orthopedic surgery, 2017, Volume: 9, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Celecoxib; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Female;	2017
Differences in Safety of Nonsteroidal Antiinflammatory Drugs in Patients With Osteoarthritis and Patients With Rheumatoid Arthritis: A Randomized Clinical Trial. Arthritis & rheumatology (Hoboken, N.J.), 2018, Volume: 70, Issue:4 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Celec	2018
Randomised clinical trial: gastrointestinal events in arthritis patients treated with celecoxib, ibuprofen or naproxen in the PRECISION trial. Alimentary pharmacology & therapeutics, 2018, Volume: 47, Issue:11 Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis, Rheumatoid; Aspi	2018
Impact of genetic polymorphisms on adenoma recurrence and toxicity in a COX2 inhibitor (celecoxib) trial: results from a pilot study. Pharmacogenetics and genomics, 2013, Volume: 23, Issue:8 Topics: Adenoma; Adenomatous Polyps; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Celecoxib; Col	2013
Comparison of the efficacy and safety profiles of a pelubiprofen versus celecoxib in patients with rheumatoid arthritis: a 6-week, multicenter, randomized, double-blind, phase III, non-inferiority clinical trial. BMC musculoskeletal disorders, 2014, Nov-18, Volume: 15 Topics: Adult; Aged; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Ede	2014
Gastrointestinal safety and efficacy of long-term GCSB-5 use in patients with osteoarthritis: A 24-week, multicenter study. Journal of ethnopharmacology, 2016, Aug-02, Volume: 189 Topics: Aged; Antirheumatic Agents; Celecoxib; Female; Gastrointestinal Diseases; Humans; Incidence; Male; M	2016
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. The New England journal of medicine, 2016, 12-29, Volume: 375, Issue:26 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cycloo	2016
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. The New England journal of medicine, 2016, 12-29, Volume: 375, Issue:26 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cycloo	2016
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. The New England journal of medicine, 2016, 12-29, Volume: 375, Issue:26 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cycloo	2016
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. The New England journal of medicine, 2016, 12-29, Volume: 375, Issue:26 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cycloo	2016
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. The New England journal of medicine, 2016, 12-29, Volume: 375, Issue:26 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cycloo	2016
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. The New England journal of medicine, 2016, 12-29, Volume: 375, Issue:26 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cycloo	2016
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. The New England journal of medicine, 2016, 12-29, Volume: 375, Issue:26 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cycloo	2016
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. The New England journal of medicine, 2016, 12-29, Volume: 375, Issue:26 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cycloo	2016
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. The New England journal of medicine, 2016, 12-29, Volume: 375, Issue:26 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cycloo	2016
A phase I study of capecitabine, irinotecan, celecoxib, and radiation as neoadjuvant therapy of patients with locally advanced rectal cancer. American journal of clinical oncology, 2010, Volume: 33, Issue:3 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitab	2010
The APC and PreSAP trials: a post hoc noninferiority analysis using a comprehensive new measure for gastrointestinal tract injury in 2 randomized, double-blind studies comparing celecoxib and placebo. Clinical therapeutics, 2012, Volume: 34, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Celecoxib; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship,	2012
The APC and PreSAP trials: a post hoc noninferiority analysis using a comprehensive new measure for gastrointestinal tract injury in 2 randomized, double-blind studies comparing celecoxib and placebo. Clinical therapeutics, 2012, Volume: 34, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Celecoxib; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship,	2012
The APC and PreSAP trials: a post hoc noninferiority analysis using a comprehensive new measure for gastrointestinal tract injury in 2 randomized, double-blind studies comparing celecoxib and placebo. Clinical therapeutics, 2012, Volume: 34, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Celecoxib; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship,	2012
The APC and PreSAP trials: a post hoc noninferiority analysis using a comprehensive new measure for gastrointestinal tract injury in 2 randomized, double-blind studies comparing celecoxib and placebo. Clinical therapeutics, 2012, Volume: 34, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Celecoxib; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship,	2012
Efficacy and tolerability of celecoxib versus naproxen in patients with osteoarthritis of the knee: a randomized, double-blind, double-dummy trial. The Journal of international medical research, 2012, Volume: 40, Issue:4 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Celecoxib; Cyclooxygenase 2 Inhibitors; Double	2012
The efficacy of rebamipide add-on therapy in arthritic patients with COX-2 selective inhibitor-related gastrointestinal events: a prospective, randomized, open-label blinded-endpoint pilot study by the GLORIA study group. Modern rheumatology, 2013, Volume: 23, Issue:6 Topics: Alanine; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Therapy, Combination; E	2013
Efficacy and tolerability of nonprescription ibuprofen versus celecoxib for dental pain. Journal of clinical pharmacology, 2002, Volume: 42, Issue:8 Topics: Adolescent; Adult; Celecoxib; Dosage Forms; Double-Blind Method; Drug Administration Schedule; Femal	2002
Cyclooxygenase-2 specific inhibitors and upper gastrointestinal tolerability in patients with osteoarthritis receiving concomitant low dose aspirin: pooled analysis of 2 trials. The Journal of rheumatology, 2005, Volume: 32, Issue:1 Topics: Aspirin; Celecoxib; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method	2005
Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies. Rheumatology (Oxford, England), 2007, Volume: 46, Issue:3 Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Celecoxib; Cyclooxygenase 2 In	2007
Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies. Rheumatology (Oxford, England), 2007, Volume: 46, Issue:3 Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Celecoxib; Cyclooxygenase 2 In	2007
Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies. Rheumatology (Oxford, England), 2007, Volume: 46, Issue:3 Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Celecoxib; Cyclooxygenase 2 In	2007
Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies. Rheumatology (Oxford, England), 2007, Volume: 46, Issue:3 Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Celecoxib; Cyclooxygenase 2 In	2007
Celecoxib for the prevention of sporadic colorectal adenomas. The New England journal of medicine, 2006, Aug-31, Volume: 355, Issue:9 Topics: Adenoma; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovas	2006
Celecoxib for the prevention of sporadic colorectal adenomas. The New England journal of medicine, 2006, Aug-31, Volume: 355, Issue:9 Topics: Adenoma; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovas	2006
Celecoxib for the prevention of sporadic colorectal adenomas. The New England journal of medicine, 2006, Aug-31, Volume: 355, Issue:9 Topics: Adenoma; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovas	2006
Celecoxib for the prevention of sporadic colorectal adenomas. The New England journal of medicine, 2006, Aug-31, Volume: 355, Issue:9 Topics: Adenoma; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovas	2006
Celecoxib for the prevention of colorectal adenomatous polyps. The New England journal of medicine, 2006, Aug-31, Volume: 355, Issue:9 Topics: Adenoma; Adenomatous Polyps; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal	2006
Celecoxib for the prevention of colorectal adenomatous polyps. The New England journal of medicine, 2006, Aug-31, Volume: 355, Issue:9 Topics: Adenoma; Adenomatous Polyps; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal	2006
Celecoxib for the prevention of colorectal adenomatous polyps. The New England journal of medicine, 2006, Aug-31, Volume: 355, Issue:9 Topics: Adenoma; Adenomatous Polyps; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal	2006
Celecoxib for the prevention of colorectal adenomatous polyps. The New England journal of medicine, 2006, Aug-31, Volume: 355, Issue:9 Topics: Adenoma; Adenomatous Polyps; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal	2006
A prospective phase I-II trial of the cyclooxygenase-2 inhibitor celecoxib in patients with carcinoma of the cervix with biomarker assessment of the tumor microenvironment. International journal of radiation oncology, biology, physics, 2007, Jan-01, Volume: 67, Issue:1 Topics: Adult; Aged; Biomarkers, Tumor; Celecoxib; Cell Hypoxia; Combined Modality Therapy; Cyclooxygenase 2	2007
Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study. Annals of the rheumatic diseases, 2008, Volume: 67, Issue:3 Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibito	2008
Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: a randomised controlled trial in patients with osteoarthritis. BMC musculoskeletal disorders, 2008, Mar-07, Volume: 9 Topics: Aged; Arthralgia; Canada; Cardiovascular Diseases; Celecoxib; Chemical and Drug Induced Liver Injury	2008
Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA, 2000, Sep-13, Volume: 284, Issue:10 Topics: Aged; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin;	2000
Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug. Arthritis and rheumatism, 2001, Volume: 44, Issue:1 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Female; Gastro	2001
Celecoxib versus diclofenac in the management of osteoarthritis of the knee. Scandinavian journal of rheumatology, 2001, Volume: 30, Issue:1 Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Aspartate Aminotra	2001

Article	Year
Cost-effectiveness analysis of branded and authorized generic celecoxib for patients with chronic pain in Japan. PloS one, 2021, Volume: 16, Issue:7 Topics: Aged; Aged, 80 and over; Celecoxib; Chronic Pain; Computer Simulation; Cost Savings; Cost-Benefit An	2021
Gastrointestinal and cardiovascular adverse events associated with NSAIDs. Expert opinion on drug safety, 2022, Volume: 21, Issue:3 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Gastrointesti	2022
Comparative safety of NSAIDs for gastrointestinal events in Asia-Pacific populations: A multi-database, international cohort study. Pharmacoepidemiology and drug safety, 2018, Volume: 27, Issue:11 Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Australia; Celecoxib; Databases, F	2018
Potentially inappropriate concomitant medicine use with the selective COX-2 inhibitor celecoxib: Analysis and comparison of spontaneous adverse event reports from Australia, Canada and the USA. Expert opinion on drug safety, 2019, Volume: 18, Issue:3 Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Australia; Canada; Cardiovascular Diseases; Ce	2019
Effects of aggregation of drug and diagnostic codes on the performance of the high-dimensional propensity score algorithm: an empirical example. BMC medical research methodology, 2013, Nov-19, Volume: 13 Topics: Adolescent; Adult; Aged; Algorithms; Arthritis; Celecoxib; Confounding Factors, Epidemiologic; Cyclo	2013
Risk of upper gastrointestinal complications associated with cyclooxygenase-2 selective and nonselective nonsteroidal antiinflammatory drugs. Pharmacotherapy, 2009, Volume: 29, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Celec	2009
Incidence and possible risk factors for clinical upper gastrointestinal events in patients taking selective cyclooxygenase-2 inhibitors: A prospective, observational, cohort study in Taiwan. Clinical therapeutics, 2010, Volume: 32, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cohort Studies;	2010
Risk of hospitalization for upper gastrointestinal adverse events associated with nonsteroidal anti-inflammatory drugs: a nationwide case-crossover study in Taiwan. Pharmacoepidemiology and drug safety, 2011, Volume: 20, Issue:7 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celec	2011
Impact of Celecoxib restrictions in medicare beneficiaries with arthritis. The American journal of managed care, 2011, Volume: 17, Issue:7 Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib;	2011
Non-steroidal anti-inflammatory drugs use and risk of upper gastrointestinal adverse events in cirrhotic patients. Liver international : official journal of the International Association for the Study of the Liver, 2012, Volume: 32, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Comorbidity; Cyc	2012
Gastrointestinal-sparing effects of novel NSAIDs in rats with compromised mucosal defence. PloS one, 2012, Volume: 7, Issue:4 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin; Celecoxib; Drug Therapy, Combi	2012
Are selective COX 2 inhibitors superior to traditional NSAIDs? Rofecoxib did not provide unequivocal benefit over traditional NSAIDs. BMJ (Clinical research ed.), 2002, Jul-20, Volume: 325, Issue:7356 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Clinical Trials as Topic;	2002
Arthritis treatment in Hong Kong--cost analysis of celecoxib versus conventional NSAIDS, with or without gastroprotective agents. Alimentary pharmacology & therapeutics, 2002, Volume: 16, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cele	2002
[Reduction of severe gastro-intestinal complications after the use of celecoxib:evidence available in the literature]. Atencion primaria, 2002, Oct-15, Volume: 30, Issue:6 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Evidence-Based Medicine; Gastrointestinal Diseas	2002
Systematic review of celecoxib for osteoarthritis and rheumatoid arthritis. Celecoxib's relative gastrointestinal safety is overstated. BMJ (Clinical research ed.), 2003, Feb-08, Volume: 326, Issue:7384 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Gastrointestinal Diseases	2003
The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis. Arthritis and rheumatism, 2003, Jun-15, Volume: 49, Issue:3 Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Canada; Cel	2003
Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed celecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data. Rheumatology (Oxford, England), 2003, Volume: 42, Issue:11 Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Anti-Inflammatory Agents, N	2003
Adverse Drug Events Involving COX-2 Inhibitors. The Annals of pharmacotherapy, 2003, Volume: 37, Issue:9 Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Anti-Inflammatory Agents, N	2003
Drug utilization review of celecoxib in Ontario. Rheumatology (Oxford, England), 2003, Volume: 42 Suppl 3 Topics: Aged; Arthritis, Rheumatoid; Celecoxib; Cost Control; Cyclooxygenase Inhibitors; Drug Utilization Re	2003
Drug switching patterns among patients with rheumatoid arthritis and osteoarthritis using COX-2 specific inhibitors and non-specific NSAIDs. Pharmacoepidemiology and drug safety, 2004, Volume: 13, Issue:5 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inh	2004
Coxibs and cardiovascular disease. The New England journal of medicine, 2004, Oct-21, Volume: 351, Issue:17 Topics: Adverse Drug Reaction Reporting Systems; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Dis	2004
Upper gastrointestinal adverse drug reactions and cyclo-oxygenase-2 inhibitors (celecoxib and rofecoxib): a case/non-case study from the French Pharmacovigilance Database. European journal of clinical pharmacology, 2004, Volume: 60, Issue:9 Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Celecoxib; Cyclooxygenase 2; Cyclo	2004
Rofecoxib, Merck, and the FDA. The New England journal of medicine, 2004, Dec-30, Volume: 351, Issue:27 Topics: Aspirin; Cardiovascular Diseases; Celecoxib; Cyclooxygenase Inhibitors; Drug Approval; Drug Interact	2004
Assessing the cost-effectiveness of COX-2 specific inhibitors for arthritis in the Veterans Health Administration. Current medical research and opinion, 2005, Volume: 21, Issue:1 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Cost-Benefit Analysis; Cyclooxy	2005
A comparison of reported gastrointestinal and thromboembolic events between rofecoxib and celecoxib using observational data. Drug safety, 2005, Volume: 28, Issue:9 Topics: Celecoxib; Cyclooxygenase Inhibitors; Gastrointestinal Diseases; Humans; Lactones; Product Surveilla	2005
Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis. Arthritis and rheumatism, 2006, Volume: 54, Issue:11 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; F	2006
Trying times for painkiller choices. Vioxx, Bextra, and Celebrex can increase the risk for heart attack and other cardiovascular problems. So can the old standbys, like ibuprofen and acetaminophen. Harvard heart letter : from Harvard Medical School, 2006, Volume: 17, Issue:2 Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxy	2006
Channelling of COX-2 inhibitors to patients at higher gastrointestinal risk but not at lower cardiovascular risk: the Cox2 inhibitors and tNSAIDs description of users (CADEUS) study. Pharmacoepidemiology and drug safety, 2007, Volume: 16, Issue:8 Topics: Adult; Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxi	2007
Balancing the risks and benefits of celecoxib. The American journal of medicine, 2007, Volume: 120, Issue:6 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Gastrointestinal Dise	2007
The relative efficacies of gastroprotective strategies in chronic users of nonsteroidal anti-inflammatory drugs. Gastroenterology, 2008, Volume: 134, Issue:4 Topics: Age Distribution; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Cardiovascular Disease	2008
Evaluating drug toxicity signals: is a hierarchical classification of evidence useful or a hindrance? Pharmacoepidemiology and drug safety, 2008, Volume: 17, Issue:5 Topics: Adult; Aged; Causality; Celecoxib; Computer Simulation; Cyclooxygenase 2 Inhibitors; Databases, Fact	2008
Celecoxib approved as NSAID with some concessions on class warning. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 1999, Mar-01, Volume: 56, Issue:5 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhibitors	1999
[Specific COX-2 inhibitor drugs: an important progress in gastroenterology]. Revista espanola de enfermedades digestivas, 1999, Volume: 91, Issue:12 Topics: Celecoxib; Cyclooxygenase Inhibitors; Gastrointestinal Diseases; Humans; Pyrazoles; Sulfonamides	1999
Cyclooxygenase 2 selective agents and upper gastrointestinal disease. JAMA, 2000, Apr-19, Volume: 283, Issue:15 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; C	2000
Cyclooxygenase 2 selective agents and upper gastrointestinal disease. JAMA, 2000, Apr-19, Volume: 283, Issue:15 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; C	2000
COX-2-Selective NSAIDs: new and improved? JAMA, 2000, Sep-13, Volume: 284, Issue:10 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygena	2000
COX-2 inhibitors. The Medical journal of Australia, 2000, Oct-16, Volume: 173, Issue:8 Topics: Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenas	2000
The Swedish ACCES model: predicting the health economic impact of celecoxib in patients with osteoarthritis or rheumatoid arthritis. Rheumatology (Oxford, England), 2000, Volume: 39 Suppl 2 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cost of Illness; Cost-Ben	2000
Selective COX-2 inhibitors. The American journal of nursing, 2001, Volume: 101, Issue:4 Topics: Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib;	2001
[Side effects cause enormous costs. Expensive arthritis therapy]. MMW Fortschritte der Medizin, 2001, Nov-15, Volume: 143, Issue:46 Topics: Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Butanones; Celecoxib;	2001
GI events leading to death in association with celecoxib and rofecoxib. The American journal of gastroenterology, 2001, Volume: 96, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Celecoxib; Cyclooxygenase Inhibitors; Gastrointestinal Diseases; Hum	2001
Increase in lifetime adverse drug reactions, service utilization, and disease severity among patients who will start COX-2 specific inhibitors: quantitative assessment of channeling bias and confounding by indication in 6689 patients with rheumatoid arthr The Journal of rheumatology, 2002, Volume: 29, Issue:5 Topics: Aged; Arthritis, Rheumatoid; Bias; Celecoxib; Confounding Factors, Epidemiologic; Cyclooxygenase 2;	2002

celecoxib and Cholera Infantum